Terminated PHASE3 INTERVENTIONAL 2-arm NCT05306574

A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Stage Trial to Evaluate Efficacy and Safety of Telitacicept Compared to Placebo in Patients With Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)

Sponsor: Vor Biopharma

Conditions Systemic Lupus Erythematosus

Interventions Placebo Telitacicept

Updated 13 times since 2022 Last updated: Jan 7, 2026 Started: Jun 20, 2022 Primary completion: Jan 6, 2025 Completion: Jan 6, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Business decision

Other terminated trials from Vor Biopharma

More terminations from Vor Biopharma

Other Systemic Lupus Erythematosus trials with similar outcome

Browse all Systemic Lupus Erythematosus trials

This PHASE3 trial investigates Systemic Lupus Erythematosus and is currently terminated or withdrawn. Vor Biopharma leads this study, which shows 13 recorded versions since 2022 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

13 versions recorded

Feb 2026 — Present [monthly]

Terminated PHASE3

Status: Active Not Recruiting → Terminated
Oct 2025 — Feb 2026 [monthly]

Active Not Recruiting PHASE3
Sep 2025 — Oct 2025 [monthly]

Active Not Recruiting PHASE3
Dec 2024 — Sep 2025 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Sep 2024 — Dec 2024 [monthly]

Recruiting PHASE3

▶ Show 8 earlier versions

Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Dec 2023 — Jul 2024 [monthly]

Recruiting PHASE3
Oct 2023 — Dec 2023 [monthly]

Recruiting PHASE3
Jul 2023 — Oct 2023 [monthly]

Recruiting PHASE3
Feb 2023 — Jul 2023 [monthly]

Recruiting PHASE3
Nov 2022 — Feb 2023 [monthly]

Recruiting PHASE3
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
May 2022 — Sep 2022 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Vor Biopharma

Data source: Vor Biopharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anniston, United States , Barranquilla, Colombia , Batangas, Philippines , Baytown, United States , Bucaramanga, Colombia , Budapest, Hungary , Bydgoszcz, Poland , Bytom, Poland , Cagayan de Oro, Philippines , Caguas, Puerto Rico and 51 more locations